ClinicalTrials.gg
CompletedNCT02890966Updated Mar 30, 2017

Multiple Dose Study of SHR4640 in Healthy Subjects

A Phase 1 interventional study of SHR4640 and placebo in Gout; Hyperuricemia, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-03-30.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Gout by Jiangsu HengRui Medicine Co., Ltd. — none open to participants now, none under way, none of them phase 3. Gout · Jiangsu HengRui Medicine Co., Ltd..

Enrollment
7th of 11
48 · median 50
Started
2016
with 1 other
Phase 1
7 of 11
none open now
Registered
2nd of 11
by date

Among the 11 studies in Gout by Jiangsu HengRui Medicine Co., Ltd., this one is the 7th largest by enrollment, is one of 2 that started in 2016, is one of 7 in phase 1, and was the 2nd registered.

Gout

347 studies on the registry are indexed under Gout; 50 are open to participants now.

Browse Gout studies →

Open to participants now

None of the 11 studies in Gout by Jiangsu HengRui Medicine Co., Ltd. is open now. The open studies under Gout, anywhere →

Where they have run

Who these studies take

Of the 31 Gout studies recruiting now, 14 (45%) set no upper age limit and 10 (32%) stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years to 55 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Gout by Jiangsu HengRui Medicine Co., Ltd. as a file.
02

Study summary

The objective of the study is to assess the tolerance, pharmacokinetic and pharmacodynamic properties of multiple dose adminstration of SHR4640 in healthy volunteers.

03

Conditions studied

  • Gout; Hyperuricemia

Browse trials for

Keywords

  • SHR4640 pharmacokinetics pharmacodynamics
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age between 18 and 55, male;
  2. Body weight≥50, :19-25kg/m2;

3.4 mg/dL≤Screening serum urate level≤7 mg/dL;

4.Medically stable based on physical examination, laboratory results, vital sign measurements, 12-lead , abdomen B-ultrasound and Chest X-ray examination at screening.

Exclusion criteria

Exclusion Criteria:

  1. Serum creatinine>(ULN);
  2. and/or Aspartate aminotransferase>2×ULN, total >1.5×ULN, glutamyltransferase>3×ULN;
  3. History of hyperuricemia or gout;
  4. History or suspicion of kidney stones;
  5. Positive results for surface antigen, antibody, antibody, syphilis antibody test.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Cohort 1

    1mg SHR4640 or placebo

    Drug: SHR4640 · Drug: placebo

  • Experimental
    Cohort 2

    2.5mg SHR4640 or placebo

    Drug: SHR4640 · Drug: placebo

  • Experimental
    Cohort 3

    5mg SHR4640 or placebo

    Drug: SHR4640 · Drug: placebo

  • Experimental
    Cohort 4

    10mg SHR4640 or placebo

    Drug: SHR4640 · Drug: placebo

Interventions

  • Day1\~Day7:oral administration

  • Drugplacebo

    Day1\~Day7:oral administration

06

What researchers measure

Primary outcomes

  1. Adverse events

    Time frame: Clinical significant changes from baseline up to Day 10

Secondary outcomes

  1. Peak Plasma Concentration(Cmax)(of single dose and at stable status)

    Time frame: Up to Day 10

  2. Area under the plasma concentration versus time curve(AUC)(of single dose and at stable status)

    Time frame: Up to Day 10

  3. Half-time(T1/2)(of single dose and at stable status)

    Time frame: Up to Day 10

  4. Time to the peak plasma concentration(Tmax)(of single dose and at stable status)

    Time frame: Up to Day 10

  5. Changes in serum uric acid concentration from baseline

    Time frame: Up to Day 10

  6. Changes in urinary uric acid excretion from baseline

    Time frame: Up to Day 10

07

Study locations

1 site
  • The South West Hospital
    Chongqing, Chongqing 400042, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2016, a primary completion of Feb 2017 and a completion of Mar 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2016
First posted
Sep 7, 2016
Start
Jul 2016
Primary completionActual
Feb 2017
CompletionActual
Mar 2017
Last update
Mar 30, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02890966
Responsible party
Sponsor
First posted
Sep 7, 2016
Start date
Jul 2016
Primary completion
Feb 2017
Completion
Mar 2017
Last update
Mar 30, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruzinurad

Start the discussion